Related Experiment Video
Updated: Jun 23, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 19, 2013
Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects
Yu-An Yang1, Oksana Dukhanina, Binwu Tang
1Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, Maryland 20892, USA.
Abstract:
TGF-betas play diverse and complex roles in many biological processes. In tumorigenesis, they can function either as tumor suppressors or as pro-oncogenic factors, depending on the stage of the disease. We have developed transgenic mice expressing a TGF-beta antagonist of the soluble type II TGF-beta receptor:Fc fusion protein class, under the regulation of the mammary-selective MMTV-LTR promoter/enhancer. Biologically significant levels of antagonist were detectable in the serum and most tissues of this mouse line. The mice were resistant to the development of metastases at multiple organ sites when compared with wild-type controls, both in a tail vein metastasis assay using isogenic melanoma cells and in crosses with the MMTV-neu transgenic mouse model of metastatic breast cancer. Importantly, metastasis from endogenous mammary tumors was suppressed without any enhancement of primary tumorigenesis. Furthermore, aged transgenic mice did not exhibit the severe pathology characteristic of TGF-beta null mice, despite lifetime exposure to the antagonist. The data suggest that in vivo the antagonist may selectively neutralize the undesirable TGF-beta associated with metastasis, while sparing the regulatory roles of TGF-betas in normal tissues. Thus this soluble TGF-beta antagonist has potential for long-term clinical use in the prevention of metastasis.
Insights
This study developed a TGF-beta antagonist in mice, effectively preventing cancer metastasis without harming normal tissues. This discovery offers potential for long-term clinical use in metastasis prevention.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Transforming growth factor-betas (TGF-betas) have dual roles in cancer, acting as tumor suppressors or promoters depending on disease stage.
- Understanding TGF-beta's complex functions is crucial for developing targeted cancer therapies.
Purpose of the Study:
- To develop and evaluate a novel soluble TGF-beta antagonist for preventing cancer metastasis.
- To assess the safety and efficacy of the antagonist in preclinical models.
Main Methods:
- Generated transgenic mice expressing a soluble type II TGF-beta receptor:Fc fusion protein under MMTV-LTR control.
- Assessed antagonist levels in serum and tissues.
- Evaluated metastasis development using tail vein assays and crosses with MMTV-neu mice.
- Monitored primary tumor development and overall pathology in aged mice.
Main Results:
- Biologically significant antagonist levels were achieved systemically.
- Transgenic mice showed resistance to metastasis at multiple sites.
- Metastasis was suppressed without increasing primary tumor growth.
- Aged mice did not develop severe pathology, unlike TGF-beta null mice.
Conclusions:
- The soluble TGF-beta antagonist selectively neutralizes pro-metastatic TGF-beta signaling.
- This approach spares essential regulatory functions of TGF-beta in normal tissues.
- The developed antagonist shows significant potential for long-term clinical application in preventing metastasis.
